Bifidobacterium bifidum H3-R2 and Its Molecular Communication within the Context of Ulcerative Colitis.
- 2022-09-12
- Journal of Agricultural and Food Chemistry 70(37)
- PubMed: 36095239
- DOI: 10.1021/acs.jafc.2c02909
Study Design
- Type
- Clinical Trial
- Population
- Mice with DSS-induced ulcerative colitis
- Methods
- In vivo experiment with a murine model.
- Animal Study
Abstract
Bifidobacteria are important mediators of immune system development within the gastrointestinal system and immunological homeostasis. The present study explored the anti-colitic activity of Bifidobacterium bifidum H3-R2 in a murine dextran sulfate sodium (DSS)-induced model of ulcerative colitis (UC). Moreover, this study offers novel insight regarding the molecular basis for the probiotic properties of B. bifidum H3-R2 by analyzing the underlying mechanisms whereby B. bifidum H3-R2-derived proteins affect the intestinal barrier. B. bifidum H3-R2 administration was sufficient to alleviate clinical manifestations consistent with DSS-induced colitis, restoring aberrant inflammatory cytokine production, enhancing tight junction protein expression, and positively impacting overall intestinal microecological homeostasis in these animals. Moreover, the bifidobacteria-derived GroEL and transaldolase (TAL) proteins were found to regulate tight junction protein expression via the NF-κB, myosin light chain kinase (MLCK), RhoA/Rho-associated protein kinase (ROCK), and mitogen-activated protein kinase (MAPK) signaling pathways, preventing the lipopolysaccharide (LPS)-mediated disruption of the intestinal epithelial cell barrier.
Keywords: B. bifidum H3-R2; colitis; dextran sulfate sodium; gut microbiota; recombinant protein.
Research Insights
| Supplement | Dose | Health Outcome | Effect Type | Effect Size | Source |
|---|